Article ; Online: Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
The Journal of surgical research
2016 Volume 208, Page(s) 93–103
Abstract: Background: Diabetes disregulates inflammatory responses and impairs vascular function in wounds. Glucagon-like peptide-1 receptor (Glp-1R) agonists are hypoglycemic agents with pleiotropic vascular protective and anti-inflammatory effects. The ... ...
| Abstract | Background: Diabetes disregulates inflammatory responses and impairs vascular function in wounds. Glucagon-like peptide-1 receptor (Glp-1R) agonists are hypoglycemic agents with pleiotropic vascular protective and anti-inflammatory effects. The therapeutic potential of a Glp-1 analogue in a diabetic rat model of excisional wound injury was investigated. Materials and methods: Excisional wounds were created on the dorsum of streptozotocin-induced diabetic rats, which received placebo or Glp-1 analogue exendin-4 (Ex4; 0.5 μg/kg/d, i.p.) for 2 wk. The final-to-initial wound area ratio was measured for 14 d. Levels of superoxide anions and proinflammatory cytokines in the wound were determined. Angiogenesis was assessed using the Matrigel assay. Expression levels of proangiogenic factors and extracellular matrix proteins were measured. Results: Ex4 restored wound closure in diabetic rats and significantly suppressed the generation of superoxide anions and interleukin-6 in wounds. The number of circulating endothelial progenitor (CD34 Conclusions: Ex4 accelerated excisional wound healing in subjects with diabetes. Glp-1R activation attenuates inflammatory response and enhances angiogenesis during the early proliferation phase of wound healing in diabetic subjects, while it enhances transforming growth factor-β/matrix metalloproteinase-mediated regeneration during the maturation phase. These results suggest that Ex4 could be used as a standard hypoglycemic agent in diabetic patients with wound injury. |
|---|---|
| MeSH term(s) | Animals ; Diabetes Mellitus, Experimental/drug therapy ; Drug Evaluation, Preclinical ; Exenatide ; Glucagon-Like Peptide 1/analogs & derivatives ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Male ; Neovascularization, Physiologic/drug effects ; Peptides/pharmacology ; Peptides/therapeutic use ; Rats, Sprague-Dawley ; Venoms/pharmacology ; Venoms/therapeutic use ; Wound Healing/drug effects |
| Chemical Substances | Hypoglycemic Agents ; Peptides ; Venoms ; Glucagon-Like Peptide 1 (89750-14-1) ; Exenatide (9P1872D4OL) |
| Language | English |
| Publishing date | 2016-09-17 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 80170-7 |
| ISSN | 1095-8673 ; 0022-4804 |
| ISSN (online) | 1095-8673 |
| ISSN | 0022-4804 |
| DOI | 10.1016/j.jss.2016.09.024 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 178: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.